10.6084/m9.figshare.11864811.v1
Motofumi Maruta
Motofumi
Maruta
Takanori Miyoshi
Takanori
Miyoshi
Naomi Matsuo
Naomi
Matsuo
Takuya Yamashina
Takuya
Yamashina
Kenji Irie
Kenji
Irie
Minako Tsuruta
Minako
Tsuruta
Hiroko Tsukada
Hiroko
Tsukada
Moeko Tsuruyama
Moeko
Tsuruyama
Masahisa Nagano
Masahisa
Nagano
Yoichi Hiraki
Yoichi
Hiraki
Clinical pharmacokinetics of oxaliplatin in a hemodialysis patient with advanced gastric cancer
Taylor & Francis Group
2020
5-fluorouracil
advanced gastric cancer
hemodialysis
oxaliplatin
pharmacokinetics
platinum concentration
2020-02-18 09:58:50
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/Clinical_pharmacokinetics_of_oxaliplatin_in_a_hemodialysis_patient_with_advanced_gastric_cancer/11864811
<p>We administered FOLFOX (oxaliplatin (L-OHP) plus infusional 5-fluorouracil (5-FU) and leucovorin) to an hemodialysis (HD) patient with advanced gastric cancer (AGC), and investigated pharmacokinetics (PKs) and dialyzability of L-OHP. The patient was a 54-year-old Japanese man with a diagnosis of inoperable AGC. FOLFOX was instituted 3 h prior to the start of a 4 h HD period with the L-OHP and 5-FU doses reduced by 50% for the first cycle, and 30% reduced dose was administered for the second cycle. We performed an analysis of the PKs of L-OHP during these two cycles. Volume of distribution and area under the curve of the 30% reduced L-OHP dose were 56.7 L and 30.0 μg·h/mL, respectively. A dose reduction of L-OHP by 30%−50% may be advisable for the initial administration, given the need for careful administration of chemotherapy in HD patients, with particular attention to the development of hematological toxicities and neuropathy.</p>